Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02469415 · ClinicalTrials.gov registry record · Phase 2
Pacritinib for Patients With Lower-Risk Myelodysplastic Syndromes (MDS)
A Phase 2 study, sponsored by M.D. Anderson Cancer Center.
- Terminated
- Registry status
- Phase 2
- Development phase
- 3
- Enrollment target
NCT02469415: Clinical Trial Phase 2 study, sponsored by M.D. Anderson Cancer Center.
NCT02469415 is a Phase 2 study that was terminated before completion, run by M.D. Anderson Cancer Center. The registered enrollment target is 3 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02469415, a Phase 2 study, was terminated before completion, sponsored by M.D. Anderson Cancer Center.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 3 participants
- Enrollment target
Study Summary
The goal of this clinical research study is to learn if pacritinib, either alone or in combination with azacitidine or decitabine, can help to control MDS. The safety of this drug and drug combination will also be studied.
Primary Outcome
The primary efficacy outcome of both parts is the overall response rate (ORR) based mainly on hematologic improvement defined by (International Working Group) IWG-2006 criteria, and which also includes complete remission (CR), partial remission (PR) and marrow complete remission.
Interventions
- DRUG Decitabine
- DRUG Pacritinib
- DRUG 5-azacitidine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2015-09-30 |
| Est. Completion | 2017-06-03 |
| Phase | Phase 2 |
Why NCT02469415 stopped before completion
NCT02469415 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 3 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (98% lower).
The record links to 0 conditions, and to 3 interventions - of which Decitabine is the first listed.
NCT02469415 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02469415 about?
NCT02469415 is a clinical study titled "Pacritinib for Patients With Lower-Risk Myelodysplastic Syndromes (MDS)". The goal of this clinical research study is to learn if pacritinib, either alone or in combination with azacitidine or decitabine, can help to control MDS. The safety of this drug and drug combination will also be studied.
What is the current status of trial NCT02469415?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 3 participants. The study started on 2015-09-30. Estimated completion is 2017-06-03.
What interventions are being tested in trial NCT02469415?
The interventions under investigation include: Decitabine (DRUG), Pacritinib (DRUG), 5-azacitidine (DRUG).
Who is sponsoring clinical trial NCT02469415?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02469415's enrollment target sits among peer trials
3 2001st of 2000 the lowest of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI